Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 08/26 10:00:13 pm
42.98 USD   +0.33%
08/27 ABBOTT LABORATO : Whiplashed investors stay skittish about St. Jude
08/26 MUDDY WATERS SA : Cnbc
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

European Medical Group Changes Drug Data-Release Policy After Criticism

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2012 | 06:28pm CEST
   By Peter Loftus 
   Of  
 

A European medical society has changed its plans for releasing results of clinical studies of liver-disease therapies after some critics said the original plan would have amounted to selective disclosure to certain investors.

The studies are expected to include potentially market-moving results of trials involving hepatitis C drugs in development at Abbott Laboratories (>> Abbott Laboratories), Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Gilead Sciences Inc. (GILD).

The European Association for the Study of the Liver now plans to publicly release summaries of most of the studies online April 4, two weeks ahead of the association's International Liver Congress meeting in Barcelona.

Under the new policy, certain studies selected to be highlighted by EASL's press office won't be made available publicly until the date and time of their presentation at the conference, which runs April 18-22. EASL didn't say which studies will be selected. However, EASL said they won't be made available in advance to non-media conference participants before the embargoes lift.

Previously, EASL had planned to make the summaries available online Thursday, but only accessible to EASL members and those registered for the conference, which includes analysts and investors. EASL also previously planned to prohibit media registered to attend the conference from reporting on the summaries until the conference.

Critics of the policy, including TheStreet.com reporter Adam Feuerstein, said the original plans amounted to selective disclosure by providing material information to people who paid to attend the conference, while unfairly leaving others in the dark.

"EASL is making these changes in light of recent criticism of its proposed policy, which suggests that 'selective distribution' of officially accepted clinical data in advance of the Congress would make our proposed embargo policy untenable," EASL said in a written statement Thursday.

The presentation of drug data at medical meetings has long posed a conundrum for companies and investors. Some conferences have made changes in their policies to address concerns.

The American Society of Clinical Oncology, for instance, used to distribute study summaries to participants at its annual meeting weeks ahead of the conference, but prohibit media from reporting the contents until the conference.

ASCO has since changed its policy so that now most summaries are posted publicly online a few weeks before the annual scientific meeting, while certain featured studies aren't publicly disclosed until the meeting.

Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute who has criticized certain medical meeting embargo policies, said EASL did the right thing.

"I think the days of conferences engaging in selective release of important study results are probably over," he said. "ASCO yielded to this truth, EASL did, and I suspect other major conferences will be that much more reluctant to now buck these precedents."

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Abbott Laboratories, Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
08/27 ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
08/26 Alere drags Abbott to court over $5.8 billion deal
08/26DJALERE : Sues Abbott to Force Merger -- Update
08/26DJALERE : Sues Abbott to Force Merger
08/26DJALERE : Sues Abbott Laboratories to Force Merger
08/26 ABBOTT LABORATORIES : to Present at Wells Fargo Healthcare Conference
08/25 ABBOTT LABORATORIES : ' Trademark Application for "QWIKWASH" Filed
More news
Sector news : Pharmaceuticals - NEC
11:29aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
11:10aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test
09:29aDJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/27 Stada shareholder AOC pushes through board reshuffle
08/26 Foreign seed firms rally behind Monsanto in Indian alliance
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04:35a Abbott Is Still A Steady Eddie, But I Wouldn't Buy Now
08/28 Singapore confirms locally transmitted Zika cases
08/26 ST.JUDE MEDICAL : A Great Short With 2.5x Risk/Reward
08/26 Alere files lawsuit to force Abbott to complete acquisition
08/26 FDA recommends Zika screening of blood components in all states and territori..
Advertisement
Financials ($)
Sales 2016 20 943 M
EBIT 2016 3 989 M
Net income 2016 2 323 M
Debt 2016 2 699 M
Yield 2016 2,42%
P/E ratio 2016 23,99
P/E ratio 2017 18,71
EV / Sales 2016 3,15x
EV / Sales 2017 3,00x
Capitalization 63 180 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 48,0 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES-4.30%63 180
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-12.84%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-10.83%210 234
ASTRAZENECA PLC7.33%173 797
More Results